AI
AURA icon

Atria Investments’s Aura Biosciences AURA Stock Holding History

Atria Investments’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-30,309
Closed -$190K – 2015
2025
Q2 		$190K Buy
+30,309
New +$177K ﹤0.01% 1932

Other funds holding AURA

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Atria Investments's AURA Position: Q3 2025 in Review

Atria Investments sold out of Aura Biosciences (AURA) in Q3 2025, closing a stake of 30,309 shares — an estimated $190K sold.

Atria Investments first reported a position in AURA in Q2 2025 and held it in 1 quarter. The position peaked at $190K in Q2 2025. 106 funds tracked by Wall St. Rank hold AURA as of Q3 2025.

  • Atria Investments reported no remaining Aura Biosciences position as of Q3 2025 after selling out during the quarter.
  • Atria Investments sold 30,309 Aura Biosciences shares in Q3 2025, an estimated $190K.
  • Atria Investments first reported a position in Aura Biosciences in Q2 2025 and held it in 1 quarter.
  • Atria Investments's Aura Biosciences position peaked at $190K in Q2 2025.
  • 106 funds tracked by Wall St. Rank held Aura Biosciences as of Q3 2025.

Based on Atria Investments's 13F filing for Q3 2025, filed 6 Nov 2025.